Data News Insights | KlickAnalytics

Editas Medicine Inc (EDIT)

EDIT is trading UP for the last 2 days, and it at trading at $5.43 with volume of 1,049,322 and a one day change of $0.11 (1.97%). Editas Medicine Inc has a 52-week low of 4.91 and a 52-week high of $11.90. The business's 50-day moving average price is $5.50 and its 200 day moving average price is $7.80. The firm has a market cap of $0 million, a P/E ratio of 0.00, and a beta of 2.05.

For more information on EDIT:

Alnylam Pharmaceuticals Inc (ALNY)

ALNY is trading UP for the last 3 days, and it at trading at $156.36 with volume of 496,764 and a one day change of $2.89 (1.88%). Alnylam Pharmaceuticals Inc has a 52-week low of 141.98 and a 52-week high of $218.88. The business's 50-day moving average price is $149.24 and its 200 day moving average price is $162.52. The firm has a market cap of $19 million, a P/E ratio of 0.00, and a beta of 0.30.

For more information on ALNY:

Regeneron Pharmaceuticals, Inc. (REGN)

REGN is trading UP for the last 2 days, and it at trading at $1,010.65 with volume of 332,381 and a one day change of $8.92 (0.89%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 684.81 and a 52-week high of $1,016.00. The business's 50-day moving average price is $959.92 and its 200 day moving average price is $930.38. The firm has a market cap of $109 million, a P/E ratio of 28.73, and a beta of 0.12.

Top news headlines for REGN

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 8:00 AM ET Company Participants Ryan Crowe - Head of IR Chris Fenimore - CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Thank you for joining us and welcome to Day 2 of the Goldman Sachs Healthcare Conference.

Approval in patients with pJIA weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica

For more information on REGN:

Laboratory Corp. Of America Holdings (LH)

LH is trading UP for the last 1 days, and it at trading at $197.20 with volume of 346,053 and a one day change of $1.28 (0.65%). Laboratory Corp. Of America Holdings has a 52-week low of 186.63 and a 52-week high of $234.09. The business's 50-day moving average price is $201.97 and its 200 day moving average price is $214.03. The firm has a market cap of $17 million, a P/E ratio of 44.59, and a beta of 1.03.

For more information on LH: